Merestinib - Eli Lilly

Drug Profile

Merestinib - Eli Lilly

Alternative Names: LY-2801653

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Dana-Farber Cancer Institute; Eli Lilly
  • Class Amides; Antineoplastics; Dihydropyridines; Pyrazoles; Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors; Proto oncogene protein c met inhibitors; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Cancer

Most Recent Events

  • 27 Sep 2017 University of Utah plans a phase I trial for Bone metastases in patients with Breast cancer (NCT03292536)
  • 12 Sep 2017 Eli Lilly completes a phase I trial in Cancer (Late-stage disease) in USA (NCT01285037)
  • 10 Aug 2017 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03125239)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top